Phathom Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
PHAT$5.25+3.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(334,326) | $(201,592) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 795 | 575 |
| Stock-based compensation | 24,047 | 45,025 |
| Issuance of PIK interest debt | 3,775 | 3,583 |
| Accrued interest on revenue interest financing liability | 46,111 | 24,727 |
| Amortization of debt discount | 2,192 | 1,877 |
| Inventory reserve | 836 | — |
| Other | 5,098 | 1,869 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (7,672) | (8,067) |
| Accounts receivable, net | (37,160) | (1,637) |
| Accounts payable and accrued expenses | 34,936 | 6,410 |
| Accrued interest | 565 | 292 |
| Operating right-of-use assets and lease liabilities | 175 | 194 |
| Inventory | (6,142) | (9,442) |
| Other long-term assets | — | (1,394) |
| Net cash used in operating activities | (266,770) | (137,580) |
| Cash flows from investing activities | ||
| Cash paid for property and equipment | (135) | (1,634) |
| Net cash used in investing activities | (135) | (1,634) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from exercise of stock options | 1,599 | 124 |
| Net proceeds from issuance of debt | 59,400 | 39,318 |
| Net proceeds from underwritten public offering | 121,775 | 141,390 |
| Net proceeds from revenue interest financing transaction | — | 172,675 |
| Net proceeds from issuance of common stock under ATM facility | — | 14,073 |
| Net cash provided by financing activities | 182,774 | 367,580 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (84,131) | 228,366 |
| Cash and cash equivalents and restricted cash – beginning of period | 384,256 | 155,890 |
| Cash and cash equivalents and restricted cash – end of period | $300,125 | $384,256 |
| Supplemental disclosure of cash flow information | ||
| Interest paid | $17,293 | $11,133 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Property and equipment purchases included in accounts payable and accrued expenses | $8 | $18 |
| Final interest payment fee | $1,800 | $2,200 |
| Settlement of ESPP liability in common stock | $2,401 | $1,417 |
| Settlement of 401(k) liability in common stock | $3,683 | $1,612 |
See accompanying notes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.